EAF6 Antibody

What is EAF6/MEAF6 and why is it significant for research?

EAF6 (Esa1-associated factor 6 homolog), also known as MEAF6 (MYST/Esa1-associated factor 6), is a nuclear protein involved in transcriptional activation and chromatin modification. It functions as a component of histone acetyltransferase complexes and the BAP1 complex, playing crucial roles in gene regulation . The protein is encoded by the MEAF6 gene (previously annotated as C1orf149) and has been implicated in various diseases including cancer and developmental disorders, making it an important target for research investigating epigenetic mechanisms and gene expression regulation .

What are the key specifications of commercially available EAF6 antibodies?

EAF6 antibodies are typically available as rabbit polyclonal antibodies, such as the 26465-1-AP and CAB14629 variants. These antibodies demonstrate reactivity with human and mouse samples and have been validated for applications including Western Blot (WB), Immunoprecipitation (IP), and ELISA . The antibodies target the full sequence or specific regions of the EAF6 protein, with observed molecular weights typically ranging from 22-28 kDa . Most are provided in liquid form with PBS storage buffer containing sodium azide and glycerol, and should be stored at -20°C for optimal stability .

What cells and tissues have confirmed EAF6 expression for positive controls?

Western blot analysis has confirmed EAF6 expression in several human cell lines including HepG2 (liver cancer cells), HeLa (cervical cancer cells), and Jurkat cells (T lymphocytes) . Mouse testis tissue has also been validated as a positive control for EAF6 detection . When establishing experimental protocols, these validated samples provide reliable positive controls for antibody performance verification.

What are the recommended antibody dilutions for different applications?

For optimal results in Western blot applications, the recommended dilution range for EAF6 antibodies is typically 1:500-1:1000 . For immunoprecipitation procedures, the suggested amount is 0.5-4.0 μg of antibody for every 1.0-3.0 mg of total protein lysate . These dilutions serve as starting points, and researchers should perform titration experiments to determine optimal concentrations for their specific experimental conditions and sample types.

How should I design controls for EAF6 antibody experiments?

A robust experimental design for EAF6 antibody application should include:

What optimization strategies improve detection of EAF6 in difficult samples?

For challenging samples where EAF6 detection is difficult, consider these optimization approaches:

• Increase antibody concentration gradually (up to 1:250 dilution) while monitoring background levels

• Extend primary antibody incubation time (overnight at 4°C instead of 1-2 hours)

• Optimize protein extraction protocols to ensure nuclear proteins are efficiently recovered, as EAF6 is primarily localized in the nucleus and nucleolus

• For low-abundance samples, consider using enhanced chemiluminescence (ECL) substrates with higher sensitivity

• Implement signal amplification techniques such as biotin-streptavidin systems when appropriate

How can EAF6 antibodies be used to investigate chromatin modification complexes?

EAF6/MEAF6 functions as a component of histone acetyltransferase complexes, making its antibodies valuable tools for chromatin research . For investigating these complexes:

• Use co-immunoprecipitation (Co-IP) with EAF6 antibodies to pull down associated complex members, followed by mass spectrometry or Western blot analysis of interacting partners

• Perform chromatin immunoprecipitation (ChIP) assays to identify genomic regions associated with EAF6-containing complexes

• Implement ChIP-seq approaches to map genome-wide binding profiles of EAF6-containing complexes

• Combine with proximity ligation assays (PLA) to visualize and quantify interactions between EAF6 and other chromatin modifiers in situ

• Use immunofluorescence with EAF6 antibodies to track its nuclear localization and potential co-localization with other factors during different cell cycle stages or in response to treatments

What considerations are important when developing specificity profiles for EAF6 antibodies?

When working with EAF6 antibodies or developing new variants with improved specificity:

• Consider computational approaches to identify and disentangle multiple binding modes associated with specific epitopes

• Evaluate cross-reactivity with related proteins, particularly other components of histone acetyltransferase complexes

• Validate antibody specificity using knockout or knockdown models where EAF6/MEAF6 expression is eliminated or reduced

• Perform epitope mapping to understand exactly which regions of the protein are recognized by the antibody

• Test reactivity across multiple species if working with model organisms beyond human and mouse systems

How can EAF6 antibodies contribute to cancer research?

EAF6/MEAF6 has been identified as a potential cancer/testis (CT) antigen and is highly expressed in some sarcomas . For cancer research applications:

• Use EAF6 antibodies to evaluate expression levels across tumor types and correlate with clinical outcomes

• Investigate potential roles in synovial sarcoma, where CT antigens show particularly high expression

• Explore connections to the BAP1 complex, which has established roles in cancer biology

• Study changes in EAF6 localization or expression during tumor progression

• Investigate potential diagnostic applications, particularly in sarcomas where EAF6/MEAF6 may serve as a biomarker

What are the most common issues when using EAF6 antibodies and how can they be resolved?

How can I validate the specificity of my EAF6 antibody results?

To ensure your EAF6 antibody results are specific and reliable:

• Perform side-by-side comparison with multiple EAF6 antibodies targeting different epitopes

• Implement genetic approaches (siRNA, CRISPR) to create EAF6/MEAF6 knockdown/knockout models and verify signal reduction

• Use recombinant EAF6 protein as a competition control to demonstrate binding specificity

• Validate results with orthogonal methods (e.g., mass spectrometry) when investigating protein interactions

• Compare observed molecular weight (22-28 kDa) with expected weight to confirm target identification

What is currently known about EAF6/MEAF6's role in gene regulation?

EAF6/MEAF6 functions as a chromatin modification-related protein involved in gene regulation . Research has revealed:

• It operates as a component of histone acetyltransferase complexes that influence gene expression through chromatin remodeling

• It has been identified as a component of the BAP1 complex, suggesting roles in tumor suppression

• Its primary localization in the nucleus and nucleolus aligns with functions in transcriptional regulation

• Studies have implicated MEAF6 in processes related to both transcriptional activation and repression, depending on the cellular context

• Dysregulation has been linked to cancer and developmental disorders, highlighting its importance in normal cellular function

How does EAF6/MEAF6 expression vary across different tissues and disease states?

While comprehensive expression profiling data is still emerging, current evidence indicates:

• EAF6/MEAF6 shows expression patterns characteristic of cancer/testis (CT) antigens, with restricted expression in normal tissues

• It demonstrates particularly high expression in synovial sarcomas

• Expression has been detected in multiple human cancer cell lines including HepG2, HeLa, and Jurkat cells

• Mouse testis tissue has shown confirmed expression, supporting the cancer/testis antigen classification

• Altered expression patterns may correlate with disease progression in certain cancer types, though more research is needed

What emerging applications of EAF6 antibodies show promise for advanced research?

Several cutting-edge applications represent promising directions for EAF6 antibody usage:

• Integration with single-cell technologies to map EAF6 expression and function at cellular resolution

• Application in spatial transcriptomics to understand tissue-specific roles of EAF6-containing complexes

• Development of highly specific EAF6 antibodies using biophysics-informed computational approaches for custom specificity profiles

• Utilization in multiparameter imaging to visualize dynamic changes in EAF6 complexes during cell state transitions

• Exploration of therapeutic applications targeting EAF6/MEAF6 in cancers where it shows aberrant expression

How might EAF6 research contribute to personalized medicine approaches?

Understanding EAF6/MEAF6's role in disease could impact precision medicine:

• As a component of chromatin-modifying complexes, EAF6/MEAF6 may influence epigenetic states relevant to treatment response

• Its potential role as a cancer biomarker, particularly in sarcomas, might aid in patient stratification

• Investigation of EAF6-related pathways could reveal novel therapeutic targets for diseases with epigenetic dysregulation

• Integration with other molecular markers could enhance diagnostic and prognostic capabilities

• Long-term, antibody-based therapeutics targeting EAF6 could be explored for specific cancer subtypes showing EAF6 dependence